Ludwig Presence at 2018 ASCO Annual Meeting June 1 5, 2018
|
|
- Teresa Holland
- 5 years ago
- Views:
Transcription
1 Ludwig Presence at 2018 ASCO Annual Meeting June 1 5, 2018 Ludwig Scientist Affiliation (s) Time Location Type Track Presentation/Abstract Title Saturday, June 2 Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #419a Poster Genitourinary (Nonprostate) Cancer Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. George Demetri Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #255 Poster Sarcoma George Demetri Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #258 Poster Sarcoma Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST) Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D) George Demetri Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #296 Poster Sarcoma Targeted tumor profiling and actionable somatic variants in sarcoma Rakesh Jain Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board: #107 Poster Breast Cancer Metastatic A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM). **scientist is senior author 1
2 Yang Liu Ludwig Laussane 8:00 11:30 AM Hall A, Poster Board: #271 Poster Sarcoma Comprehensive genomic profiling of sarcomas in Chinese population. Matt Van De Rijn Ludwig Stanford 8:00 11:30 AM Hall A, Poster Board: #288 Poster Sarcoma CDKN2A deletion as a prognostic marker: A clinicogenomic analysis of sarcoma patients Maximilian Diehn Ludwig Stanford 8:00 9:15 AM S406 Education Therapeutics and Translational Research Liquid Biopsies: Current Uses and Future Directions - Methods and Applications of cfdna Analysis Sushama Varma Ludwig Stanford 8:00 11:30 AM Hall A, Poster Board: #308 Poster Sarcoma Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma Ralph Weichselbaum Ludwig Chicago 9:30 AM - 12:00 PM Hall B1 Opening Special s Opening With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture Sandro Santagata Ludwig Harvard 1:15-2:30 PM S100bc Education Central Nervous System Tumors Clinical Trials Therapeutics and Translational Research Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice Jedd Wolchok Ludwig MSK 1:15-2:30 PM S100a Education Special s ASCO/Radiological Society of North America (RSNA) Joint : Assessing Response and Progression With Targeted Thera and Immunothera - Immune-Related Response and RECIST in Radiographic Imaging Stephen Hodi Ludwig Harvard 1:15-4:45 PM Hall A, Poster Board: #169 Poster Central Nervous System Tumors Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort **scientist is senior author 2
3 Joshua Cohen Ludwig John Hopkins 1:15-4:45 PM Hall A, Poster Board #61 Poster Head and Neck Cancer Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiothera (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran s health data. Joshua Cohen Ludwig John Hopkins 1:15-4:45 PM Hall A, Poster Board #338 Poster Health Services Research, Clinical Informatics, and Quality of Care Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (ansclc). Margaret Callahan** Ludwig MSK 3:00-6:00 PM Hall B1 Oral Abstract ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients (pts) with advanced cancers. Margaret Callahan Ludwig MSK 3:00-6:00 PM Hall B1 Oral Abstract Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. Ravindra Majeti, Irving L. Weissman Ludwig Stanford 3:00-6:00 PM Hall B1 Oral Abstract A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-cd47 monoclonal antibody (mab), in patients with advanced solid tumors. Stephen Hodi Ludwig Harvard 1:15-4:45 PM E451, Poster Board #169 Central Nervous System Tumors Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort Sunday, June 3 Rakesh Jain Ludwig Harvard 8:00 11:30 AM Hall A, Poster Board #305 Poster Gastrointestinal Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study. **scientist is senior author 3
4 Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein Ludwig John Hopkins 8:00 11:30 AM Hall A, Poster Board #9 Poster Gastrointestinal (Colorectal) Cancer Serial circulating tumor DNA (ctdna) analysis as a prognostic marker and a real-time indicator of adjuvant chemothera (CT) efficacy in stage III colon cancer (CC). Yang Liu Ludwig Laussane 8:00-11:30 AM Hall A, Poster Board #241 Poster Gastrointestinal Comparison of clinical outcome and safety after minimally invasive esophagectomy: Ivor Lewis versus McKeown A real-world multicenter observational study from China. Taha Merghoub Ludwig MSK 8:00 11:30 AM Hall A, Poster Board #327b Poster Gastrointestinal A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-tace) in patients (pts) with liver limited hepatocellular carcinoma (HCC). Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus** Ludwig New York 8:00 11:30 AM Hall A, Poster Board: #428b Poster Lung Cancer Non-Small Cell Metastatic Phase 1/2 study of mrna vaccine thera + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein Ludwig John Hopkins 11:30 AM 12:45 PM Hall D2, Poster Board #9 Gastrointestinal (Colorectal) Cancer Serial circulating tumor DNA (ctdna) analysis as a prognostic marker and a real-time indicator of adjuvant chemothera (CT) efficacy in stage III colon cancer (CC). Monday, June 4 Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #250 Poster Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors. Benjamin Izar*, Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #288 Poster Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. **scientist is senior author 4
5 Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #228 Poster Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. Stephen Hodi Ludwig Harvard 8:00-11:30 AM Hall A, Poster Board: #315a Poster Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine Bianca Santomasso, Margaret Callahan** Ludwig MSK 8:00-11:30 AM Hall A, Poster Board: #298 Poster Neurologic immune related adverse events (iraes) in patients treated with immune checkpoint blockade. Michael Postow** Ludwig MSK 8:00-11:30 AM Hall A, Poster Board: #309 Poster Michael Postow, Jedd Wolchok** Ludwig MSK 8:00-11:30 AM Hall A, Poster Board: #227 Poster Pharmacodynamic and clinical activity of RGX-104, a firstin-class immunothera targeting the liver-x nuclear hormone receptor (LXR), in patients with refractory malignancies. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. Matt Van De Rijn, Maximilian Diehn, Ash Alizadeh Ludwig Stanford 8:00 11:30 AM Hall A, Poster Board: #209 Poster Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA. Stephen Hodi Ludwig Harvard 11:30-12:45 AM Hall B1, Poster Board: #228 Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. Michael Postow, Jedd Wolchok** Ludwig MSK 11:30-12:45 AM Hall B1, Poster Board: #227 Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. **scientist is senior author 5
6 Ralph Weichselbaum Ludwig Chicago 1:15 4:45 PM Hall A, Poster Board: #252 Poster Gynecologic Cancer Benjamin Izar Ludwig Harvard 1:15 4:45 PM Hall A, Poster Board: #386 Poster Melanoma/Skin Cancers Benjamin Izar Ludwig Harvard 1:15 4:45 PM Hall A, Poster Board: #408 Poster Melanoma/Skin Cancers A phase 1/2A trial of synthetic DNA vaccine immunothera targeting HPV-16 and -18 after chemoradiation for cervical cancer. Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunothera. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunothera resistance Stephen Hodi, Jedd Wolchok Ludwig Harvard 1:15 4:45 PM Hall A, Poster Board: #343 Poster Melanoma/Skin Cancers 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001 Margaret Callahan, Michael Postow, Jedd Wolchok** Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #388 Poster Melanoma/Skin Cancers Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination thera in patients with cutaneous and unknown primary melanoma. Stephane Pourpe, Hyejin Choi, Taha Merghoub, Jedd Wolchok** Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #173 Poster Immunobiology Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models. Teresa Rasalan, Dmitriy Zamarin, Phillip Wong Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #280 Poster Gynecologic Cancer A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. Dmitriy Zamarin Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #258 Poster Gynecologic Cancer The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer. **scientist is senior author 6
7 Jedd Wolchok, Michael Postow** Ludwig MSK 1:15 4:45 PM Hall A, Poster Board: #379 Poster Melanoma/Skin Cancers Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma. Michael Postow*, Danielle McCabe, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus Ludwig MSK; Ludwig New York 1:15 4:45 PM Hall A, Poster Board: #377 Poster Melanoma/Skin Cancers Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiothera (RT) in patients with metastatic melanoma. Anthony Letai Ludwig Harvard 4:30 6:00 PM E450 Clinical Science Symposium Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). Stephen Hodi, Jedd Wolchok Ludwig Harvard 1:15 4:45 PM E451, Poster Board #343 Melanoma/Skin Cancers 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001 Publication-only Abstracts Muriel Laine*, Marianne Greene, Ya- Fang Chang, Geoffrey Greene** Ludwig Chicago N/A N/A Publication-only abstracts Breast Cancer Metastatic Lasofoxifene efficacy in a mammary intraductal (MIND) xenograft model of ERα+ breast cancer. Rakesh Jain Ludwig Harvard N/A N/A Publication-only abstracts Gastrointestinal Angiotensin system inhibitors during induction chemothera for esophageal adenocarcinoma: Analysis of survival. Joshua Cohen Ludwig John Hopkins N/A N/A Publication-only abstracts Healthy Services Research, Clinical Informatics, and Quality of Care Cost-effectiveness of adjuvant chemothera in early stage breast cancer. **scientist is senior author 7
8 Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein Ludwig John Hopkins N/A N/A Publication-only abstracts Gastrointestinal Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer. Yang Liu Ludwig Laussane N/A N/A Publication-only abstracts Lung Cancer Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers A real-world observational study to explore clinical characteristics of Chinese patients with T1 non-small cell lung cancer complicated with lymph metastases. Yang Liu Ludwig Laussane N/A N/A Publication-only abstracts Lung Cancer Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Surgical treatments of Chinese patients with lung malignant tumors. Matthew Vander Heiden Ludwig MIT N/A N/A Publication-only abstracts Gastrointestinal Association between changing body composition after diagnosis and survival of patients with advanced pancreatic cancer. Michael Postow*, Jedd Wolchok Ludwig MSK N/A N/A Publication-only abstracts Tumor Biology Imaging of tumor infiltrating T cells with an anti-cd8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. Michael Postow, Margaret Callahan, Jedd Wolchok Ludwig MSK N/A N/A Publication-only abstracts Melanoma/Skin Cancers Multigene sequencing, co number alteration detection, and survival with first-line PD-1 based thera in patients with mucosal melanoma. Jedd Wolchok, Margaret Callahan Ludwig MSK N/A N/A Publication-only abstracts Safety of influenza vaccination in patients undergoing immunothera treatment for advanced cancer. Margaret Callahan Ludwig MSK N/A N/A Publication-only abstracts Patient and Survivor Care Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors. **scientist is senior author 8
9 Michael Postow, Margaret Callahan, Jedd Wolchok Ludwig MSK N/A N/A Publication-only abstracts Melanoma/Skin Cancers Multigene sequencing, co number alteration detection, and survival with first-line PD-1 based thera in patients with mucosal melanoma. Kanika Arora, Taha Merghoub Ludwig MSK N/A N/A Publication-only abstracts Melanoma/Skin Cancers Clonal evolution of uveal melanoma metastases. Danny Khalil Ludwig MSK N/A N/A Publication-only abstracts Healthy Services Research, Clinical Informatics, and Quality of Care Total parenteral nutrition utilization in metastatic cancer patients: A nationwide 10-year analysis from 2006 to Michael Postow, Mary Macri, Ralph Venhaus, Jedd Wolchok Ludwig MSK; Ludwig New York N/A N/A Publication-only abstracts Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma. **scientist is senior author 9
Ludwig Presence at 2016 ASCO Annual Meeting
Ludwig Scientist(s) Affiliation(s) Session and Presentation Time Location Track Session Type/Title Presentation and/or Abstract Title Friday, June 3, 2016 Luisa Lina Villa Ludwig Sao Paulo 1:00pm - 3:15pm
More informationLudwig Presence at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Ludwig Scientist(s) Affiliation(s) Keywords Abstract/Presentation Category Presentation/Abstract Title & Time FRIDAY, NOVEMBER 10 Arlene Sharpe (session chair) Ludwig Harvard N/A Science Behind the Therapy:
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationRoche Investor Relations ASCO Planner 2017
Roche Investor Relations ASCO Planner 2017 Saturday, June 3 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Sat, June 3 Time: 8:00 AM 11:30 AM Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi,
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationNCIC Clinical Trials Group ASCO Annual Meeting Presentations
Saturday, June 1 Session Title: Central Nervous System Tumors IND.204 - Poster Board: #3A Phase II study of PX-866 in recurrent glioblastoma. (Abstract #2053) Marshall W. Pitz, MD FRCPC Session Title:
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationLudwig Presence at 2016 AACR Annual Meeting
Ludwig Scientist (s) Affiliation (s) Time Location Type Title Presentation/Abstract Title & Time SATURDAY, APRIL 16 Crystal Mackall Ludwig Stanford 8:00am - 10:00am Educational Using Tumor Biology to Drive
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationHistorical overview of immunotherapy
Historical overview of immunotherapy Before introduction of immune checkpoint inhibitors John B.A.G. Haanen, MD PhD My Disclosures I have provided consultation, attended advisory boards, and/or provided
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCarla van Herpen Medical Oncologist Immunotherapyin Head & NeckCancer
Carla van Herpen Medical Oncologist 01-10-2016 Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial,
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More information:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationRoche Investor Relations ASCO Planner 2014
Roche Investor Relations ASCO Planner 2014 F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations email: investor.relations@roche.com Tel. +41 61 68-88880 Fax +41 61 69-10014 www.roche.com
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationDuke at. American Society of Clinical Oncology Chicago, Illinois
Duke at American Society of Clinical Oncology 2017 Chicago, Illinois Duke Medicine Divisions of Hematology Medical Oncology and Hematologic Malignancy & Cellular Therapy Cordially invite you to the Duke
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationASCO 2018 Summary of Presentation. May 16, 2018
ASCO 2018 Summary of May 16, 2018 ASCO: Accepted s Oral presentations DS-8201 Pexidartinib Poster discussions U3-1402 Quizartinib DS-3032 Poster presentations Trial-in-Progress DS-8201 U3-1402 DS-1062
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationSteamboat Springs, Colorado. January 15-18, 2016
Friday, January 15, 2016 Registration: Begins at 2:00 pm Plenary Session: 4:00 pm - 6:00 pm 14 th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 15-18, 2016 Current Status
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationJose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma
Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre Evolution of liver resection Better understanding
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationDevelopment status of OPDIVO (nivolumab) 1
May 12, 2017 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Non-small cell lung cancer (2 nd ~) Approved Approved Approved *) Non-small
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationASCP Immuno-Oncology Scientific Updates Liquid Biopsies: Current Limitations and Potential Applications
ASCP Scientific Updates: Liquid Biopsies: Current Limitations and Potential Applications December 2018 Faculty Alexander J Lazar MD, PhD Professor Departments of Pathology, Genomic Medicine, & Translational
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationRoche Investor Relations ASCO Planner 2018
Roche Investor Relations ASCO Planner 2018 Friday, June 1 Session Title: Hematologic Malignancies Plasma Cell Dyscrasia Date: Fri, June 1 Time: 2:45 PM - 5:45 PM Speaker Name: Luciano J. Costa 3:57 PM
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationHall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404
23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationDevelopmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer. Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018
Developmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018 Disclosure Information 23 rd Annual Developmental Therapeutics
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More information